Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryohei Katayama

Showing results (21-30 of 107) with videos related to

Pageof 11
Sort By:
Scientific Reports|July 19, 2017
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activityHayato Ogura, Yuka Nagatake-Kobayashi, Jun Adachi, et al.
Biochemical and Biophysical Research Communications|June 19, 2024
3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancerAkari Shiraishi, Tomoko Oh-Hara, Yuki Takahashi, et al.
Molecular Cancer Therapeutics|October 15, 2014
Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistanceAki Aoyama, Ryohei Katayama, Tomoko Oh-Hara, et al.
Cancer Science|March 18, 2021
Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agentsTakao Ukaji, Ai Takemoto, Harumi Shibata, et al.
Molecular Cancer Therapeutics|July 29, 2017
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged CancersMiho J Fuse, Koutaroh Okada, Tomoko Oh-Hara, et al.
Journal of Cell Science|December 18, 2009
Modulation of Wnt signaling by the nuclear localization of cellular FLIP-LRyohei Katayama, Toshiyasu Ishioka, Shinji Takada, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2025
Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancerSho Kakuto, Ken Uchibori, Yuri Yamamoto, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2026
Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicityMasaru Yokomura, Seiji Nagano, Hiroshi Kawamoto, et al.
Cancer Science|February 4, 2025
AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive FibroblastsTakahiro Utsumi, Hayato Mizuta, Yosuke Seto, et al.
Nature Communications|March 14, 2017
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerKen Uchibori, Naohiko Inase, Mitsugu Araki, et al.
Pageof 11

Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
Scientific Reports|July 19, 2017
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activityHayato Ogura, Yuka Nagatake-Kobayashi, Jun Adachi, et al.
Biochemical and Biophysical Research Communications|June 19, 2024
3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancerAkari Shiraishi, Tomoko Oh-Hara, Yuki Takahashi, et al.
Molecular Cancer Therapeutics|October 15, 2014
Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistanceAki Aoyama, Ryohei Katayama, Tomoko Oh-Hara, et al.
Cancer Science|March 18, 2021
Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agentsTakao Ukaji, Ai Takemoto, Harumi Shibata, et al.
Molecular Cancer Therapeutics|July 29, 2017
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged CancersMiho J Fuse, Koutaroh Okada, Tomoko Oh-Hara, et al.
Journal of Cell Science|December 18, 2009
Modulation of Wnt signaling by the nuclear localization of cellular FLIP-LRyohei Katayama, Toshiyasu Ishioka, Shinji Takada, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2025
Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancerSho Kakuto, Ken Uchibori, Yuri Yamamoto, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2026
Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicityMasaru Yokomura, Seiji Nagano, Hiroshi Kawamoto, et al.
Cancer Science|February 4, 2025
AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive FibroblastsTakahiro Utsumi, Hayato Mizuta, Yosuke Seto, et al.
Nature Communications|March 14, 2017
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerKen Uchibori, Naohiko Inase, Mitsugu Araki, et al.
Pageof 11